The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer

被引：0
|
作者：
Yang Zhang
Yuanyuan Zeng
Ting Liu
Wenwen Du
Jianjie Zhu
Zeyi Liu
Jian-an Huang
机构：
[1] the First Affiliated Hospital of Soochow University,Department of Respiratory Medicine
[2] Suzhou Key Laboratory for Respiratory Diseases,undefined
[3] Institute of Respiratory Diseases,undefined
[4] Soochow University,undefined
来源：
Respiratory Research | / 20卷
关键词：
PD-L1; EGFR-TKI; Drug resistance; TGF-β/Smad signalling; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
    Hu, Di
    Zhou, Yan-Yan
    Ma, Hong-Bo
    Tao, Miao-Miao
    Huang, Qun-Zhen
    Yang, Zhen-Zhou
    Zhou, Qi
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [22] ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
    Dantong Sun
    Fei Teng
    Puyuan Xing
    Junling Li
    Molecular Medicine, 2021, 27
  • [23] ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
    Sun, Dantong
    Teng, Fei
    Xing, Puyuan
    Li, Junling
    MOLECULAR MEDICINE, 2021, 27 (01)
  • [24] High Tumour PD-L1 Is Associated With Poor Outcomes in EGFR-Mutant Lung Cancer Treated With First Generation EGFR TKIs
    Liu, J.
    Itchins, M.
    Nagrial, A.
    Cooper, W.
    De Silva, M.
    Barnet, M.
    Varikatt, W.
    Sivasubramaniam, V.
    Davis, A.
    Gill, A.
    Blinman, P.
    Lee, K.
    Hui, R.
    Gao, B.
    Pavlakis, N.
    Clarke, S.
    Lee, J.
    Boyer, M.
    Kao, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S588 - S589
  • [25] Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis
    He, Mingfeng
    Wu, Xue
    Li, Li
    Yi, Guangming
    Wang, Yitian
    He, Hengqiu
    Ye, Ying
    Zhou, Ruiqin
    Xu, Zaicheng
    Yang, Zhenzhou
    RADIATION ONCOLOGY, 2025, 20 (01)
  • [26] PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
    Mei Ji
    Yan Liu
    Qing Li
    Xiao-Dong Li
    Wei-Qing Zhao
    Hanze Zhang
    Xiaofei Zhang
    Jing-Ting Jiang
    Chang-Ping Wu
    Journal of Translational Medicine, 13
  • [27] PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
    Ji, Mei
    Liu, Yan
    Li, Qing
    Li, Xiao-Dong
    Zhao, Wei-Qing
    Zhang, Hanze
    Zhang, Xiaofei
    Jiang, Jing-Ting
    Wu, Chang-Ping
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [28] Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
    Wang, Shuhang
    Su, Xiaomei
    Bai, Hua
    Zhao, Jun
    Duan, Jianchun
    An, Tongtong
    Zhuo, Minglei
    Wang, Zhijie
    Wu, Meina
    Li, Zhenxiang
    Zhu, Jian
    Wang, Jie
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [29] Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
    Yulong Fu
    Yang Zhang
    Zhe Lei
    Ting Liu
    Tingting Cai
    Anqi Wang
    Wenwen Du
    Yuanyuan Zeng
    Jianjie Zhu
    Zeyi Liu
    Jian-an Huang
    Journal of Hematology & Oncology, 13
  • [30] Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
    Shuhang Wang
    Xiaomei Su
    Hua Bai
    Jun Zhao
    Jianchun Duan
    Tongtong An
    Minglei Zhuo
    Zhijie Wang
    Meina Wu
    Zhenxiang Li
    Jian Zhu
    Jie Wang
    Journal of Hematology & Oncology, 8
12345